≥99% HPLCPre-filled pen

CJC-1295 (no DAC)

Name: CJC-1295 (no DAC)
Brand: Dripfy
Availability: InStock

What it is?

CJC-1295 (no DAC), also known as Mod-GRF 1-29, is a short-acting, research-grade analog of growth-hormone-releasing hormone (GHRH). It belongs to the GHRH-analog family and is studied for its influence on the growth-hormone / IGF-1 axis; it is not an approved medicine.

Dripfy Advantage

GHRH-receptor pathway: understood to engage pituitary GHRH receptors and prompt pulsatile growth-hormone release (hedged).
Short-acting profile: without the Drug Affinity Complex (DAC), its action is brief, so it is investigated as a pulse secretagogue rather than a sustained one.
IGF-1 axis signalling: may influence downstream IGF-1 signalling as part of the same axis.
Physician-directed: Any regimen is determined solely by the supervising physician.

Research & Investigational Focus

GH / IGF-1 support: investigated for growth-hormone and IGF-1 axis support.
Lean-mass & recovery: studied within lean-mass and recovery research contexts.
Body composition & sleep: explored for body-composition and sleep-quality signalling.

Composition & Formulation

Format: Pre-filled pen
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€496

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

CJC-1295 (no DAC)

GHRH analog (investigational) · Pre-filled pen

D· Preliminary evidence

CJC-1295 without DAC (Mod-GRF 1-29) is a modified fragment of growth-hormone-releasing hormone. It is understood to bind GHRH receptors on the anterior pituitary and to prompt pulsatile release of endogenous growth hormone, which may in turn influence IGF-1 signalling. Without the Drug Affinity Complex its action is short-lived, so it is investigated as a pulse secretagogue rather than a sustained one. Human evidence remains limited and the mechanism is drawn largely from GHRH-analog research.

Studied use areas

Investigated for growth-hormone / IGF-1 axis support
Studied within lean-mass and recovery research
Explored for body-composition and sleep-quality signalling
Researched alongside other GH secretagogues in the GH-axis literature

Safety & status

Investigational; robust human safety data are limited
Use only under qualified physician supervision
Not for use in pregnancy or breastfeeding, or with active or suspected malignancy (GH/IGF-1 axis considerations)

⚕ Clinical note: CJC-1295 (no DAC) is an investigational, research-grade peptide and not an approved medicine. It is intended for physician-directed use only, and this content is educational, not medical advice.

Evidence: Grade D — investigational; limited human data, mainly preclinical · References: Teichman et al., Journal of Clinical Endocrinology & Metabolism 2006; Ionescu & Frohman, Journal of Clinical Endocrinology & Metabolism 2006; Sigalos & Pastuszak, Sexual Medicine Reviews 2018